Darren R Feldman1, James Hu2, Tanya B Dorff2, Kristina Lim2, Sujata Patil2, Kaitlin M Woo2, Maryann Carousso2, Amanda Hughes2, Joel Sheinfeld2, Manjit Bains2, Siamak Daneshmand2, Charlene Ketchens2, Dean F Bajorin2, George J Bosl2, David I Quinn2, Robert J Motzer2. 1. Darren R. Feldman, Kristina Lim, Sujata Patil, Kaitlin M. Woo, Maryann Carousso, Amanda Hughes, Joel Sheinfeld, Manjit Bains, Dean F. Bajorin, George J. Bosl, and Robert J. Motzer, Memorial Sloan Kettering Cancer Center; Darren R. Feldman, Dean F. Bajorin, George J. Bosl, and Robert J. Motzer, Weill Medical College of Cornell University, New York, NY; and James Hu, Tanya B. Dorff, Siamak Daneshmand, Charlene Ketchens, and David I. Quinn, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA. feldmand@mskcc.org. 2. Darren R. Feldman, Kristina Lim, Sujata Patil, Kaitlin M. Woo, Maryann Carousso, Amanda Hughes, Joel Sheinfeld, Manjit Bains, Dean F. Bajorin, George J. Bosl, and Robert J. Motzer, Memorial Sloan Kettering Cancer Center; Darren R. Feldman, Dean F. Bajorin, George J. Bosl, and Robert J. Motzer, Weill Medical College of Cornell University, New York, NY; and James Hu, Tanya B. Dorff, Siamak Daneshmand, Charlene Ketchens, and David I. Quinn, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA.
Abstract
PURPOSE: Paclitaxel, ifosfamide, and cisplatin (TIP) achieved complete responses (CRs) in two thirds of patients with advanced germ cell tumors (GCTs) who relapsed after first-line chemotherapy with cisplatin and etoposide with or without bleomycin. We tested the efficacy of first-line TIP in patients with intermediate- or poor-risk disease. PATIENTS AND METHODS: In this prospective, multicenter, single-arm phase II trial, previously untreated patients with International Germ Cell Cancer Collaborative Group poor-risk or modified intermediate-risk GCTs received four cycles of TIP (paclitaxel 240 mg/m(2) over 2 days, ifosfamide 6 g/m(2) over 5 days with mesna support, and cisplatin 100 mg/m(2) over 5 days) once every 3 weeks with granulocyte colony-stimulating factor support. The primary end point was the CR rate. RESULTS: Of the first 41 evaluable patients, 28 (68%) achieved a CR, meeting the primary efficacy end point. After additional accrual on an extension phase, total enrollment was 60 patients, including 40 (67%) with poor risk and 20 (33%) with intermediate risk. Thirty-eight (68%) of 56 evaluable patients achieved a CR and seven (13%) achieved partial responses with negative markers (PR-negative) for a favorable response rate of 80%. Five of seven achieving PR-negative status had seminoma and therefore did not undergo postchemotherapy resection of residual masses. Estimated 3-year progression-free survival and overall survival rates were 72% (poor risk, 63%; intermediate risk, 90%) and 91% (poor risk, 87%; intermediate risk, 100%), respectively. Grade 3 to 4 toxicities consisted primarily of reversible hematologic or electrolyte abnormalities, including neutropenic fever in 18%. CONCLUSION: TIP demonstrated efficacy as first-line therapy for intermediate- and poor-risk GCTs with an acceptable safety profile. Given higher rates of favorable response, progression-free survival, and overall survival compared with prior first-line studies, TIP warrants further study in this population.
PURPOSE:Paclitaxel, ifosfamide, and cisplatin (TIP) achieved complete responses (CRs) in two thirds of patients with advanced germ cell tumors (GCTs) who relapsed after first-line chemotherapy with cisplatin and etoposide with or without bleomycin. We tested the efficacy of first-line TIP in patients with intermediate- or poor-risk disease. PATIENTS AND METHODS: In this prospective, multicenter, single-arm phase II trial, previously untreated patients with International Germ Cell Cancer Collaborative Group poor-risk or modified intermediate-risk GCTs received four cycles of TIP (paclitaxel 240 mg/m(2) over 2 days, ifosfamide 6 g/m(2) over 5 days with mesna support, and cisplatin 100 mg/m(2) over 5 days) once every 3 weeks with granulocyte colony-stimulating factor support. The primary end point was the CR rate. RESULTS: Of the first 41 evaluable patients, 28 (68%) achieved a CR, meeting the primary efficacy end point. After additional accrual on an extension phase, total enrollment was 60 patients, including 40 (67%) with poor risk and 20 (33%) with intermediate risk. Thirty-eight (68%) of 56 evaluable patients achieved a CR and seven (13%) achieved partial responses with negative markers (PR-negative) for a favorable response rate of 80%. Five of seven achieving PR-negative status had seminoma and therefore did not undergo postchemotherapy resection of residual masses. Estimated 3-year progression-free survival and overall survival rates were 72% (poor risk, 63%; intermediate risk, 90%) and 91% (poor risk, 87%; intermediate risk, 100%), respectively. Grade 3 to 4 toxicities consisted primarily of reversible hematologic or electrolyte abnormalities, including neutropenic fever in 18%. CONCLUSION: TIP demonstrated efficacy as first-line therapy for intermediate- and poor-risk GCTs with an acceptable safety profile. Given higher rates of favorable response, progression-free survival, and overall survival compared with prior first-line studies, TIP warrants further study in this population.
Authors: Stuart Hinton; Paul J Catalano; Lawrence H Einhorn; Craig R Nichols; E David Crawford; Nicholas Vogelzang; Donald Trump; Patrick J Loehrer Journal: Cancer Date: 2003-04-15 Impact factor: 6.860
Authors: G Daugaard; I Skoneczna; N Aass; R De Wit; M De Santis; H Dumez; S Marreaud; L Collette; J R G Lluch; C Bokemeyer; H J Schmoll Journal: Ann Oncol Date: 2010-11-08 Impact factor: 32.976
Authors: G Varuni Kondagunta; Jennifer Bacik; Alessia Donadio; Dean Bajorin; Stephanie Marion; Joel Sheinfeld; George J Bosl; Robert J Motzer Journal: J Clin Oncol Date: 2005-09-20 Impact factor: 44.544
Authors: Robert J Motzer; Craig J Nichols; Kim A Margolin; Jennifer Bacik; Paul G Richardson; Nicholas J Vogelzang; Dean F Bajorin; Primo N Lara; Lawrence Einhorn; Madhu Mazumdar; George J Bosl Journal: J Clin Oncol Date: 2007-01-20 Impact factor: 44.544
Authors: Thomas A Olson; Matthew J Murray; Carlos Rodriguez-Galindo; James C Nicholson; Deborah F Billmire; Mark D Krailo; Ha M Dang; James F Amatruda; Claire M Thornton; G Suren Arul; Sara J Stoneham; Farzana Pashankar; Daniel Stark; Furqan Shaikh; David M Gershenson; Allan Covens; Jean Hurteau; Sally P Stenning; Darren R Feldman; Peter S Grimison; Robert A Huddart; Christopher Sweeney; Thomas Powles; Luiz Fernando Lopes; Simone dos Santos Agular; Girish Chinnaswamy; Sahar Khaleel; Sherif Abouelnaga; Juliet P Hale; A Lindsay Frazier Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Samuel A Funt; Deaglan J McHugh; Stephanie Tsai; Andrea Knezevic; Devon O'Donnell; Sujata Patil; Deborah Silber; Maria Bromberg; Maryann Carousso; Victor E Reuter; Brett S Carver; Joel Sheinfeld; Robert J Motzer; Dean F Bajorin; George J Bosl; Darren R Feldman Journal: Oncologist Date: 2021-03-12
Authors: Alexander I Rolevich; Denis M Borodin; Anton N Rabcheuski; Tatsiana A Ivanitskaya; Sviataslau A Semenov; Liudmila V Artsiushkevich; Alena V Sukalinskaya; Edvard A Zhavrid; Sergei A Krasny; Natalia E Konoplya; Sergey L Polyakov Journal: JCO Glob Oncol Date: 2021-01
Authors: Michal Mego; Katarina Rejlekova; Daniela Svetlovska; Vera Miskovska; Ad J M Gillis; Valentina De Angelis; Katarina Kalavska; Jana Obertova; Patrik Palacka; Maria Reckova; Zuzana Sycova-Mila; Daniel Pindak; Michal Chovanec; Leendert H J Looijenga; Jozef Mardiak Journal: Eur Urol Open Sci Date: 2021-09-22